These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 25497280)

  • 21. HJURP involvement in de novo CenH3(CENP-A) and CENP-C recruitment.
    Tachiwana H; Müller S; Blümer J; Klare K; Musacchio A; Almouzni G
    Cell Rep; 2015 Apr; 11(1):22-32. PubMed ID: 25843710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
    Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
    Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.
    Karn T; Ruckhäberle E; Hanker L; Müller V; Schmidt M; Solbach C; Gätje R; Gehrmann M; Holtrich U; Kaufmann M; Rody A
    Breast Cancer Res Treat; 2011 Nov; 130(2):409-20. PubMed ID: 21203899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes.
    Li JY; Jia S; Zhang WH; Zhang Y; Kang Y; Li PS
    Asian Pac J Cancer Prev; 2013; 14(5):3197-203. PubMed ID: 23803104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2.
    Kalashnikova EV; Revenko AS; Gemo AT; Andrews NP; Tepper CG; Zou JX; Cardiff RD; Borowsky AD; Chen HW
    Cancer Res; 2010 Nov; 70(22):9402-12. PubMed ID: 20864510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study.
    Healey MA; Hirko KA; Beck AH; Collins LC; Schnitt SJ; Eliassen AH; Holmes MD; Tamimi RM; Hazra A
    Breast Cancer Res Treat; 2017 Nov; 166(2):613-622. PubMed ID: 28791482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Licensing of Centromeric Chromatin Assembly through the Mis18α-Mis18β Heterotetramer.
    Nardi IK; Zasadzińska E; Stellfox ME; Knippler CM; Foltz DR
    Mol Cell; 2016 Mar; 61(5):774-787. PubMed ID: 26942680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.
    Kuo WH; Chang YY; Lai LC; Tsai MH; Hsiao CK; Chang KJ; Chuang EY
    PLoS One; 2012; 7(9):e45831. PubMed ID: 23049873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of frequencies and prognostic effect of molecular subtypes between young and elderly breast cancer patients.
    de Kruijf EM; Bastiaannet E; Rubertá F; de Craen AJ; Kuppen PJ; Smit VT; van de Velde CJ; Liefers GJ
    Mol Oncol; 2014 Jul; 8(5):1014-25. PubMed ID: 24767310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.
    Yousef EM; Furrer D; Laperriere DL; Tahir MR; Mader S; Diorio C; Gaboury LA
    Mod Pathol; 2017 May; 30(5):682-697. PubMed ID: 28084344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
    Sørlie T; Wang Y; Xiao C; Johnsen H; Naume B; Samaha RR; Børresen-Dale AL
    BMC Genomics; 2006 May; 7():127. PubMed ID: 16729877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of methylation sites and signature genes with prognostic value for luminal breast cancer.
    Xiao B; Chen L; Ke Y; Hang J; Cao L; Zhang R; Zhang W; Liao Y; Gao Y; Chen J; Li L; Hao W; Sun Z; Li L
    BMC Cancer; 2018 Apr; 18(1):405. PubMed ID: 29642861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mislocalization of the centromeric histone variant CenH3/CENP-A in human cells depends on the chaperone DAXX.
    Lacoste N; Woolfe A; Tachiwana H; Garea AV; Barth T; Cantaloube S; Kurumizaka H; Imhof A; Almouzni G
    Mol Cell; 2014 Feb; 53(4):631-44. PubMed ID: 24530302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Octameric CENP-A nucleosomes are present at human centromeres throughout the cell cycle.
    Padeganeh A; Ryan J; Boisvert J; Ladouceur AM; Dorn JF; Maddox PS
    Curr Biol; 2013 May; 23(9):764-9. PubMed ID: 23623556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.
    Ramirez-Ardila DE; Ruigrok-Ritstier K; Helmijr JC; Look MP; van Laere S; Dirix L; Berns EM; Jansen MP
    Mol Oncol; 2016 Oct; 10(8):1363-73. PubMed ID: 27491861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Xenopus laevis M18BP1 Directly Binds Existing CENP-A Nucleosomes to Promote Centromeric Chromatin Assembly.
    French BT; Westhorpe FG; Limouse C; Straight AF
    Dev Cell; 2017 Jul; 42(2):190-199.e10. PubMed ID: 28743005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.